Mabpharm (SEHK:2181) First Profitable Year Tests Bullish Earnings Growth Narrative

Mabpharm (SEHK:2181) has reported its FY 2025 first half results with revenue of C¥274.2 million and basic EPS of C¥0.000702, while trailing 12 month figures show revenue of C¥646.1 million and basic EPS of C¥0.01 as the business moves through its first year of profitability. Over the past reported periods, revenue has shifted from C¥108.5 million in 1H FY 2024 to C¥149.7 million in 2H FY 2024 and then to C¥274.2 million in 1H FY 2025, with net income moving from a loss of C¥97.6 million in 1H FY 2024 to a profit of C¥2.9 million in 1H FY 2025, pointing to a healthier margin profile that investors will be watching closely.

See our full analysis for Mabpharm.

With the headline numbers set, the next step is to see how this shift into profitability lines up with the most widely held narratives about Mabpharm and where those stories may need updating.

Curious how numbers become stories that shape markets? Explore Community Narratives

TTM profit of C¥57.1 million after years of losses

• On a trailing twelve month basis, Mabpharm has C¥646.1 million in revenue and C¥57.1 million in net income, compared with losses of C¥127.9 million on C¥258.2 million of revenue in the earlier TTM period shown. This highlights how the move into profit is backed by higher revenue over the past year rather than just a one half year swing.
• What stands out for bullish investors is that this recent profitability sits alongside a reported 5 year earnings growth rate of 27.3% a year, yet the company only just crossed into the black. This raises questions about how much of that long term growth reflects the current C¥57.1 million profit and how much is tied to earlier loss making years that are now falling out of the comparison.
  • Supporters may point to the C¥2.9 million profit in 1H FY 2025 versus a C¥97.6 million loss in 1H FY 2024 as evidence that the business model is now working on a half year basis as well as over the TTM period.
  • At the same time, the fact that trailing EPS of C¥0.01 only recently turned positive means the bullish story still rests on relatively fresh profitability, which some readers may want to see sustained across more periods.

Readers who want to see how this fresh profit fits into the bigger picture of growth and valuation can go deeper into the community view with the Curious how numbers become stories that shape markets? Explore Community Narratives.

P/E of 35.1x versus peers on 37x

• Mabpharm is trading on a trailing P/E of 35.1x, compared with 36.9x for peers and 37.1x for the broader Asian biotech industry. The market is therefore putting a slightly lower multiple on the same C¥0.01 of trailing EPS than it does on sector comparables, despite the company only recently turning profitable.
• Bullish arguments that the stock offers relative value are partly supported by this small P/E gap. However, the same data set also shows a DCF fair value of HK$0.17 against a current share price of HK$0.55, which challenges the idea that the shares are simply cheap on fundamentals.
  • Fans of the bullish view can point out that the P/E discount is modest and sits alongside reported 27.3% annual earnings growth over five years, which some will see as enough to justify paying in line with other biotechs.
  • Others will focus on the roughly three times difference between the HK$0.55 market price and the HK$0.17 DCF fair value and argue that this tension makes it important to understand exactly what assumptions are baked into each valuation approach.

Profit covers interest weakly as price stays volatile

• Alongside the new C¥57.1 million of trailing net income, the risk summary flags that earnings do not comfortably cover interest payments and that the share price has been highly volatile over the past three months compared with the Hong Kong market. As a result, the quality of this first year of profit is being judged alongside financing and trading risk.
• Bears highlight these points to argue that the recent profit may not fully offset balance sheet and market risk, and the numbers in the past year give them some support.
  • The shift from a TTM loss of C¥127.9 million in the earlier period to a profit of C¥57.1 million improves the story, yet weak interest coverage means a meaningful portion of that profit is still being viewed through the lens of debt servicing capacity.
  • When a stock is both highly volatile and trading above an HK$0.17 DCF fair value at HK$0.55, cautious readers may treat the new profitability as only one part of a broader risk reward trade off rather than a complete answer to earlier concerns.

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Mabpharm's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

The mix of fresh profit and flagged risks paints a balanced picture, so it makes sense to review the numbers yourself and decide where you stand. To help you consider both sides quickly, start with the 1 key reward and 2 important warning signs.

See What Else Is Out There

Mabpharm’s new profitability still comes with weak interest coverage, a premium to its DCF fair value and a share price described as highly volatile.

If that mix of fresh profits and financing plus price swings feels uncomfortable, compare it with companies in the 284 resilient stocks with low risk scores to find ideas with calmer risk profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com